Yarrow Bioscience, Inc. (YARW)
13.56
-0.67
(-4.71%)
USD |
NASDAQ |
Nov 20, 12:22
Yarrow Bioscience Cash from Operations (Quarterly) : -89.96M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -89.96M |
| June 30, 2026 | -1.992M |
| March 31, 2026 | -4.081M |
| December 31, 2025 | -3.764M |
| September 30, 2025 | -7.096M |
| June 30, 2025 | -10.80M |
| March 31, 2025 | -11.46M |
| December 31, 2024 | -8.999M |
| September 30, 2024 | -8.51M |
| June 30, 2024 | -8.481M |
| March 31, 2024 | -7.982M |
| December 31, 2023 | -5.137M |
| September 30, 2023 | -5.152M |
| June 30, 2023 | -9.574M |
| March 31, 2023 | -5.478M |
| December 31, 2022 | -3.875M |
| September 30, 2022 | -7.125M |
| June 30, 2022 | -8.225M |
| March 31, 2022 | -9.975M |
| December 31, 2021 | -10.02M |
| Date | Value |
|---|---|
| September 30, 2021 | -17.54M |
| June 30, 2021 | -16.26M |
| March 31, 2021 | -12.55M |
| December 31, 2020 | -25.38M |
| September 30, 2020 | -23.64M |
| June 30, 2020 | -35.86M |
| March 31, 2020 | -52.21M |
| December 31, 2019 | -22.25M |
| September 30, 2019 | -21.79M |
| June 30, 2019 | -12.72M |
| March 31, 2019 | -16.64M |
| December 31, 2018 | -16.62M |
| September 30, 2018 | -12.17M |
| June 30, 2018 | -12.65M |
| March 31, 2018 | -11.29M |
| December 31, 2017 | -10.19M |
| September 30, 2017 | -12.51M |
| June 30, 2017 | 0.037M |
| March 31, 2017 | -5.584M |
| December 31, 2016 | -4.549M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Cypherpunk Technologies, Inc. | -2.902M |
| Cue Biopharma, Inc. | -10.08M |
| Faeth Therapeutics, Inc. | -13.00M |
| Indaptus Therapeutics, Inc. | -1.245M |
| Pyxis Oncology, Inc. | -16.29M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -5.00M |
| Cash from Financing (Quarterly) | 265.03M |
| Free Cash Flow | -99.79M |
| Free Cash Flow Per Share (Quarterly) | -3.982 |
| Free Cash Flow to Equity (Quarterly) | -89.96M |
| Free Cash Flow to Firm (Quarterly) | -89.96M |
| Free Cash Flow Yield | -64.14% |